Clinical trial · Interventional
Screening for Liver Cancer With CT vs. Ultrasound in Patients With Advanced Liver Disease
Screening for Hepatocellular Carcinoma With Triphasic Helical CT vs. US With Alpha-fetoprotein in Patients With Advanced Liver Disease
NCT01350167CI-TRIAL-00004910unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether ultrasound or CT scanning is more effective at detecting early liver cancer in patients with advanced liver disease.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cirrhosis | — | UNRESOLVED | — |
| End Stage Liver Disease | — | UNRESOLVED | — |
| Hepatitis C | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Screening | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Triphasic CT
- description
- Triphasic CT of the abdomen with and without contrast every 12 months with alpha-fetoprotein every 6 months.
- interventionNames
- Procedure: Screening
- type
- ACTIVE_COMPARATOR
- label
- Ultrasound
- description
- Ultrasound of the upper left quadrant with alpha-fetoprotein testing every 6 months.
- interventionNames
- Procedure: Screening
Primary outcomes (1)
- measure
- Efficacy of screening measure to detect very early/early stage HCC (Barcelona Clinic Liver Cancer Staging System)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * liver biopsy or clinical diagnosis compatible with advanced liver fibrosis or cirrhosis * potential candidate for treatment of HCC * imaging study involving the liver in the last 12 months without evidence for HCC * must be a veteran in VISN 23 Exclusion Criteria: * active or untreated malignancy other than non-melanoma skin cancer * patients with advanced medical conditions such as severe cardiovascular disease, COPD, or severe end-stage liver disease * patients unable to receive intravenous contrast due to advanced kidney disease or severe allergy * history of liver mass identified on imaging study
References
Publications (1)
- DERIVEDPocha C, Dieperink E, McMaken KA, Knott A, Thuras P, Ho SB. Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography -- a randomised study. Aliment Pharmacol Ther. 2013 Aug;38(3):303-12. doi: 10.1111/apt.12370. Epub 2013 Jun 10. PMID 23750991